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ABSTRACT
Acute promyelocitic leukemia (APL) is characterized by the pathognomonic 
presence in leukemic blasts of the hybrid protein PML/RARA, that acts as a 
transcriptional repressor impairing the expression of genes that are critical to myeloid 
differentiation. Here, we show that primary blasts from APL patients express lower 
levels of the oncosuppressor protein PTEN, as compared to blast cells from other 
AML subtypes or normal bone marrow, and demonstrate that PML-RARA directly 
inhibits PTEN expression. We show that All-Trans Retinoic Acid (ATRA) triggers in APL 
cells an active chromatin status at the core regulatory region of the PTEN promoter, 
that allows the binding of the myeloid-regulating transcription factor PU.1, and, in 
turn, the transcriptional induction of PTEN. ATRA, via PML/RARA degradation, also 
promotes PTEN nuclear re-localization and decreases expression of the PTEN target 
Aurora A kinase. In conclusion, our findings support the notion that PTEN is one of 
the primary targets of PML/RARA in APL
INTRODUCTION
Acute Promyelocytic Leukemia (APL) is 
characterized by the presence of the hybrid protein 
Promyelocytic Leukemia / Retinoic Acid Receptor 
Alpha (PML-RARA) originated by the t(15;17) balanced 
chromosomal translocation. The chimeric protein has 
pleiotropic effects and induces APL disease onset and 
progression [1, 2], by impairing the formation of functional 
PML nuclear bodies (PML NBs) [3], downregulating 
tumor suppressor genes [4, 5] through the recruitment of 
chromatin remodeling enzymes (e.g. co-repressor proteins 
and histone deacetylases) on their promoters [6], and 
deregulating transcriptional factors that are critical for 
myeloid differentiation [6-8]. The precise leukemogenic 
mechanism of the PML/RARA oncoprotein has not been 
fully elucidated, and its presence in transgenic mice is 
not per se sufficient to cause leukemia, but leads to a 
myeloproliferative syndrome [6-9]. Despite this, leukemic 
cells are addicted to PML/RARA and its degradation is 
associated with complete remission of the disease [10]. 
Peculiar to APL is the exquisite sensitivity to all-
trans retinoic acid (ATRA) treatment. Pharmacological 
doses of ATRA are capable of reverting the leukemic 
phenotype, enabling terminal differentiation of 
promyelocytic blasts and disease remission [11-14]. ATRA 
is thought to act not only by antagonizing PML-RARA-
dependent gene regulation, thereby favoring terminal 
differentiation, but also by degrading the hybrid protein in 
leukemia initiating cells (LICs) [14, 15].
In the myeloid compartment, PU.1, an ETS 
transcription factor known to regulate myeloid 
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differentiation, has a well-established role in leukemia 
suppression [16, 17]. Silencing of PU.1 in the adult 
hematopoietic tissue produces dysfunctional stem cells 
and impairs granulopoiesis, by inducing a maturation 
block [18]. Furthermore, its inactivation causes myeloid 
leukemia in rats [19] and in irradiated mice [20, 21]. 
Interestingly, PU.1 interacts with both RARA and PML/
RARA, and while PML/RARA has been demonstrated to 
downregulate PU.1 [22], ATRA treatment restores PU.1 
levels [22], thus suggesting a tumor suppressive role of 
PU.1 in APL, through the transcriptional regulation of 
specific downstream target genes.
Phosphatase and Tensin homologue deleted 
on chromosome 10 (PTEN) is a protein and lipid 
phosphatase [23] with potent oncosuppressive functions, 
which is frequently inactivated in solid tumors [23]. 
Interestingly, PTEN also plays a pivotal role in the self-
renewal of hematopoietic stem cells since its ablation 
has been demonstrated to promote exhaustion of normal 
hematopoietic stem cells (HSCs), and generation of 
leukemia-initiating cells (LICs) [24, 25]. Unexpectedly, 
however, only rare PTEN somatic mutations or genetic 
deletions have been reported in patients with acute 
myeloid leukemia (AML), including APL [26]. Notably, 
the study of hypomorphic PTEN mouse models, 
demonstrates that even subtle downregulation of PTEN 
levels can increase cancer susceptibility and favor tumor 
progression in specific tissues [27].
Here, we show that primary APL blasts are 
characterized by significantly lower levels of PTEN 
compared to blasts from other AML subtypes or normal 
bone marrow. We demonstrate that PML/RARA is directly 
involved in the downregulation of PTEN expression, while 
ATRA-treatment increases PTEN levels by inducing PU.1 
transcriptional activity. 
Our findings unveil a novel essential oncogenic 
activity of PML/RARA and further decrypt the 
mechanistic explanation of ATRA efficacy in eradicating 
t(15;17) APL.
RESULTS
PTEN expression is downregulated in APL 
compared to other AML subtypes
PTEN mRNA level was measured using quantitative 
RT-PCR in 42 APL patients (mean value 1.5 ± 0.8), and 
compared to that of 42 AML patients (mean value 2.6±1.2) 
and 6 normal bone marrow (NBM) (mean 3.5±2.5) (Figure 
1a). AML samples were characterized by heterogeneous 
PTEN expression, which was significantly higher than 
that of APL (p< 0.0001). PTEN protein levels in APL 
(n=28 samples, mean + SEM: 0.42 ± 0.42) were also 
significantly lower than that of other AML (n=30 samples, 
mean + SEM: 1.4 ± 0.6) (p<0.0001) (Figure 1b).
ATRA induces PTEN expression
To study possible mechanisms dampening PTEN 
levels in APL, we took advantage of a panel of PML/
RARA-positive and –negative cell lines. Following in 
vitro treatment of the PML/RARA positive NB4 cells 
with ATRA, PTEN mRNA and protein expression stably 
increased in a time-and dose-dependent manner (Figure 
2a-b). Dimethyl sulfoxide (DMSO) was used as a control. 
Similarly, ex vivo experiments on primary blasts from 
two APL patients showed that PTEN mRNA and protein 
expression levels increased over time during ATRA 
treatment, up to 2.5 and 4.6 folds at 72 hours, respectively 
(Figure 2c-d).
Interestingly, up-regulation of PU.1 levels upon 
ATRA treatment has been described by Gu and colleagues 
in U937 [28], a PML/RARA negative histiocytic 
lymphoma cell line. Accordingly, treatment with ATRA 
promoted upregulation of PU.1 (and PTEN) both in PML/
RARA-positive NB4 cells (Figure 2e) and in the PML/
RARA-negative OCI-AML2 and HL-60 AML cell lines 
Figure 1: PTEN expression is significantly higher in primary AML compared to APL and normal bone marrow (NBM) 
samples. a. PTEN mRNA expression level, ns: no significative by unpaired t test. ***: p<0.0005 by unpaired t test. b. PTEN protein 
expression level. ***: p<0.0005. The nonparametric Mann–Whitney U test was used to compare continuous variables according to different 
groups.
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Figure 2: Effect of ATRA, ATO and PML/RARA on PTEN expression. a. PTEN mRNA levels steadily increase in lysates from 
NB4 cells treated with ATRA, compared to DMSO. **: p<0.005 by unpaired t test. b. PTEN protein levels steadily increase in a time- and 
dose dependent manner in lysates from NB4 cells treated with ATRA, compared to DMSO. **: p<0.005 by unpaired t test. c. Induction of 
PTEN mRNA by ATRA in primary APL samples. d. PTEN protein is induced by ATRA in primary APL samples. e. Upon ATRA treatment, 
there is a parallel increase of PU.1 and PTEN protein expression. f. PTEN and PU.1 protein levels steadily increase upon ATRA treatment 
in lysates from OCI-AML2 and HL60 cells. g. ATO induces PTEN mRNA expression in lysates from NB4 cells. h. PML/RARA protein is 
induced at 2 hours in PR9 cells treated with ZnSO4 and results in a decrease of PTEN mRNA. The position of the PML/RARA protein is 
indicated by the arrowhead. i. PML/RARA reduces PTEN half-life. HEK293T cells transfected with GFP-PTEN and PSG5-PML/RARA 
constructs or GFP-PTEN and (PSG5) control plasmid were treated with cycloheximide (CHX) (100µg/ml) over 24 hours. PML/RARA 
enhanced PTEN degradation at 24 hours. **: p<0.005 by unpaired t test. j. Proteasome inhibition rescues PTEN expression. The addition of 
the proteasome inhibitor MG132 to HEK293T cells transfected with the GFP-PTEN and PSG5-PML/RARA constructs or with GFP-PTEN 
and PSG5 control plasmid rescues PTEN from PML/RARA-induced degradation.
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(Figure 2f), definitely suggesting the existence of PML/
RARA-dependent and -independent mechanisms by which 
ATRA can induce PU.1 transcription. 
PML/RARA and PTEN expression are inversely 
correlated
In order to establish whether the effect of ATRA on 
PTEN was due to direct induction rather than to PML/
RARA deprivation, we treated NB4 cells with 1µM 
Arsenic Trioxide (ATO), which is known to be able to 
degrade the PML/RARA protein without interfering with 
PTEN promoter. We observed about 60% enhancement of 
PTEN mRNA expression during the first 24 hours (Figure 
2g). 
To further investigate the possible connection 
between PTEN transcriptional regulation and PML/RARA 
expression, we used PR9 cells, a cell line expressing 
PML/RARA through a Zinc-inducible promoter. 100 
µM ZnSO4 induced expression of PML/RARA at 2 to 4 
hours, concomitant with a significant decrease of PTEN 
mRNA (Figure 2h). PML/RARA however dropped to 
very low levels 8 hours after Zinc induction, while PTEN 
transcript levels almost fully normalized (Figure 2h), 
strongly supporting the role for PML/RARA in PTEN 
transcriptional regulation.
To investigate whether PTEN regulation by PML/
RARA occurred also at the post-translational level, we 
measured the protein life span in the presence or absence 
of the hybrid transcript. We co-transfected kidney 
epithelial HEK293T cancer cells with GFP-PTEN and 
PSG5-PML/RARA constructs or with GFP-PTEN and 
PSG5 control plasmid. Treatment of these cells with 
cycloheximide inhibited protein neo-synthesis at time 
zero. In the presence of PML/RARA, PTEN half-life 
decreased at 24 hours compared to control (0.91±0.02 vs 
0.18±0.07, p = 0.004, Figure 2i). To further investigate 
the mechanism of PTEN degradation by PML/RARA, we 
then treated HEK293T cells with the proteasome inhibitor 
MG132, 24 hours after transfection with GFP-PTEN and 
PSG5-PML/RARA constructs, or with GFP-PTEN and 
PSG5 control plasmid. GFP-PTEN protein was degraded 
in the presence of PML/RARA while its level was stable 
in the control. Inhibition of proteasome function by 
cycloheximide rescued GFP-PTEN from PML/RARA-
induced degradation (figure 2j). 
Overall, these data demonstrate that PML/RARA 
impairs PTEN tumor suppressive functions by promoting 
the transcriptional repression of the PTEN gene and also 
increasing its degradation. This is fully coherent with the 
fact that PML-RARA can also interfere with PML function 
and its ability to oppose HAUSP, hence causing PTEN 
nuclear exclusion [5] and its rapid turnover.
PU.1 strongly binds to the PTEN promoter 
after PML/RARA degradation, and promotes 
chromatin activation in the PTEN core promoter 
region.
We analyzed the PTEN promoter region for 
putative regulatory sequences and identified two RARE, 
three PU.1, and one PU.1/RARE half motifs (Figure 
3a). Interestingly, ATRA is known to strongly induce 
PU.1 expression in APL cells, leading to neutrophil 
differentiation [22].
In order to mechanistically define the possible role 
of PML/RARA and PU.1 in PTEN gene transcription, we 
transfected NB4 cells using a PTEN promoter luciferase 
reporter construct, containing the 2Kb regulatory sequence 
upstream the ATG. ATRA treatment resulted in a strong 
activation of luciferase at 48 hours (Figure 3b), indicating 
the relevance of these regulatory motifs for the expression 
of PTEN. Then, we performed a ChIP assay on NB4 cells 
to analyze binding of PML/RARA and PU.1 to the putative 
regulatory sequences of the PTEN promoter (Figure 3c). 
GAPDH amplification was used as a negative control in 
all experiments. As shown in Figure 3c, ATRA increased 
PU.1 binding to the PTEN promoter region, in particular 
to the PU.1/RARE half motif (-2207 to -2163), 24 hours 
after treatment. At the same time, the amount of PML/
RARA bound to these regions significantly decreased 
(Figure 3c). 
It is known that PML/RARA inhibits PTEN gene 
expression in NB4 cells mainly via histone de-acetylation. 
The ChIP assay showed that ATRA treatment for 24 hours 
increased the acetylation status of lysine 14 on histone 3 
(H3K14ac), a mark of transcriptionally active chromatin, 
in the PTEN promoter region surrounding the ATG 
transcription initiation site (Figure 3a and 3d). On the 
contrary, no changes in the transcriptional repressive mark 
H3K27me3 were detected in the same region (Figure 3d).
These results indicate that reduction of PML/RARA 
in APL due to ATRA treatment [29] unlocks PTEN and 
PU.1 promoters, inducing an increase in PU.1 and PTEN 
expression.
ATRA treatment of NB4 cells restores PTEN 
nuclear localization and function
We previously demonstrated that Aurora A (serine/
threonine protein kinase 6), which is part of the machinery 
controlling cell cycle progression, is regulated by PTEN 
via APC/C activation, APC-CDH1 complex formation and 
consequent ubiquitination and degradation [30]. As we 
previously reported [3], treatment of NB4 cells with 1µM 
ATRA for 48 hours induced progressive PTEN protein 
accumulation and nuclear re-localization (Figure 4a). 
Importantly, protein quantification on Western blot showed 
a continuous decrement of Aurora A protein to a maximum 
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Figure 3: Regulation of PTEN expression. a. The sequence of the promoter region of PTEN with indication of putative RARE and 
PU.1 binding sites is shown. Canonical retinoic acid responsive elements (RAREs) comprise direct repeats (DR) of two [A/G]G[G/T]TCA 
[RARE half (RAREh)], separated by five (DR5) or two (DR2) random nucleotides. Sequences in boxes 1, 2, 3 and 4 represent amplified 
regions. The TSS site is underline. The ATG site is underlined. b. Luciferase expression of NB4 cells electrophorated with either PGL4-
PTEN promoter or PGL4 backbone construct, after 48hours of ATRA treatment. c. ATRA treatment enhances binding of PU.1 to the 
PTEN promoter region, while binding of PML/RARA decreases. The degree of PU.1and PML/RARA binding to DNA was measured in 
NB4 cells by a quantitative ChIP assay after treatment with ATRA. Data are shown as fold-enrichment of ChIP DNA versus input DNA. 
GAPDH was used as a negative control. Graphics 1, 2, and 3 match the amplified regions boxed in figure 3a. All data shown in the figure 
are representative of at least three independent experiments. *: p<0.05 by unpaired t test. d. Modifications of the histone markers, H3K14Ac 
and H3K27Me3, at the PTEN promoter region, by ChIP assays. Quantitative ChIP assays were performed to examine the acetylation 
and methylation of histone, H3K14Ac (white bars) and H3K27Me3 (black bars), at the promoter region of PTEN in NB4 cells after 
treatment with ATRA. The bars represent the relative levels of the q-PCR product of PTEN promoter associated with these specific histone 
modifications under the indicated conditions after immunoprecipitation with histone-specific antibodies, normalized to the H3 total level. 
Data are shown as fold enrichment of ChIP DNA versus input DNA. The bars represent the mean ± SD. GAPDH was used as negative 
control. Graphics 2,3 and 4 match the amplified regions boxed in figure 3a. All data shown in the figure are representative of at least three 
independent experiments. *: p<0.05 by unpaired t test.
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Figure 4: ATRA treatment restores PTEN localization and function. a. Microscopy analysis of PTEN localization in NB4 cells 
treated with 1mM ATRA for 48 hours b. Time course treatment of NB4 cells with 1mM ATRA and analysis of Aurora A, p-AKT and PTEN 
expression levels.
Oncotarget66393www.impactjournals.com/oncotarget
of three folds at 48 hours (Figure 4b), thus proving that 
also in APL nuclear PTEN triggers APC/CDH1-dependent 
Aurora A degradation.
PTEN is known to negatively regulate pAKT levels, 
which are low in APL and APL cell lines as NB4. ATRA 
treatment of NB4 cells induced PTEN expression together 
with AKT phosphorylation, but the mechanism involves 
other actors that precede and shunt out PTEN activity 
(Figure 4c).
DISCUSSION
PU.1 downregulation or suppression causes AML 
[19-21], suggesting its pivotal role as tumor suppressor 
gene also in acute leukemia. Recent insights disclose a role 
of PU.1 in HSCs, as regulator of cell cycle, by limiting 
HSC proliferation and preserving HSC functional integrity. 
A positive auto-regulatory loop has been described 
in HSCs of adult mice to guarantee adequate PU.1 
expression [31]. Similar to PTEN [32], PU.1 mediates its 
functions via gradual fluctuations in its expression levels. 
A tight regulation of PU.1 expression is critical for cell 
fate determination in the endothelial and hematopoietic 
compartments and in the hematopoietic lineages. It is 
expressed at low levels in uncommitted stem cells and 
prevents excessive proliferation, as levels increase, there is 
loss of proliferative potential and commitment, with higher 
levels promoting hematopoietic over endothelial fate. 
During B-cell development, PU.1 level decreases, whereas 
it increases during macrophage development [33-35]. In 
myeloid leukemic cells, PU.1 overexpression induces 
differentiation [22]. In particular, restoring sufficient levels 
of PU.1 functional protein can partially overcome the 
maturation arrest mediated by the PML/RARA and PLZF/
RARA fusion proteins [36]. Of note, PU.1 overexpression 
does not per se interfere with LICs and does not cure the 
disease [17]. Factors that induce transcriptional activation 
in PML/RARA-transformed cells suffice just to initiate 
differentiation, whereas only a profound and long-lasting 
deprivation of PML/RARA function causes the loss of 
clonogenic activity, dissociating simple maturation of still 
leukemogenic blasts from true eradication of LICs [14].
We show here that PTEN expression is directly 
suppressed by PML/RARA, which binds to PTEN 
promoter, and that degradation of the hybrid protein by 
ATRA or arsenic trioxide promotes PTEN expression in 
cells harboring the t(15;17) translocation. Actually ATRA-
treatment, restores an active chromatin status at the PTEN 
core promoter region, and induces PTEN transcription 
by inducing PU.1 expression and its recruitment to 
specific recognition motifs in the PTEN promoter region. 
Importantly, ATRA-treatment re-localizes PTEN in the 
Figure 5: A model of leukemogenesis induced by PTEN deregulation. PML/RARA inhibits the transcription of RA target 
genes, thus blocking myeloid differentiation, and prevents PU.1 binding to the PTEN promoter region. This causes a major decrease of 
PTEN production that, together with reduced PTEN lifespan due to its ubiquitination and cytoplasmatic localization, highly contributes to 
compromise its anti-oncogenic activity. In time, this may lead to the development of leukemia initiating progenitors.
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nucleus of differentiating cells and this impacts on the 
abundance of the APC-CDH1-target Aurora A. Therefore, 
as depicted by our model (Figure 5), the PTEN promoter 
region is repressed in APL by the PML/RARA repressor 
complex, while residual amount of PTEN is exported 
from the nucleus to the cytoplasm, and degraded. In 
this scenario, the lack of PTEN anticancer control could 
play a pivotal role by favoring cellular proliferation and 
survival, in turn allowing the accumulation of additional 
genetic events towards leukemogenesis, as suggested by 
the latency between expression of the hybrid protein and 
leukemia onset in PML/RARA transgenic mice [6, 9].
The mechanisms of ATRA-induced differentiation 
are various: among others, it directly induces PU-1 [22] 
and PTEN expression, beyond removing PML/RARA 
blockage. This is in line with our finding that ATRA 
induces PU.1 and PTEN expression in different AML cell 
lines regardless of the presence of PML/RARA. This may 
also suggest that PTEN and PU.1 upregulation could be 
relevant to the antitumoral effects of ATRA in other AML 
subtypes, beyond APL.
MATERIALS AND METHODS
Primary patient samples
Bone marrow samples were collected at diagnosis 
from AML and APL patients, treated at the Department 
of Hematology of the University Tor Vergata of Rome. 
Infiltration of bone marrow by leukemic blasts was >70% 
in all patients included in the study. APL diagnosis was 
confirmed in all cases by detection of the disease-specific 
PML-RARA fusion gene. Written informed consent to 
the study was obtained from all patients, and the study 
has been approved by the IRB of Policlinico Tor Vergata, 
Rome.
Cell line culture and treatment
The human cell lines Oci-AML2, HL60, the APL-
derived cell line NB4 carrying the t(15;17) translocation 
and expressing the PML/RARA fusion protein, and PR9 
(a zinc-inducible PML/RARA model constructed from the 
U937 cell line) [4] were grown at 37°C in a humidified 
atmosphere of 5% CO2 in air, in RPMI medium (GIBCO-
BRL, Grand Island, NY, USA), supplemented with 10% 
fetal bovine serum (FBS) (GIBCO-BRL, Grand Island, 
NY, USA), 20 mM Hepes, 100 g/mL penicillin and 100 
g/mL streptomycin (GIBCO-BRL, Grand Island, NY, 
USA). These cell lines were kindly provided by Emanuela 
Colombo, European Institute of Oncology, Milan. ATRA, 
ATO and ZnSO4 (all from Sigma-Aldrich, Steinheim, 
Germany), were respectively dissolved in DMSO (10 mM 
stock solution, SS), and sterile water (1 MSS).
Western blot analysis
Cell pellets were re-suspended in lysis buffer 
containing 10 mMTris–HCl (pH 7.4), 5 mM EDTA, 150 
mMNaCl, 1% Triton X-100, 250 µM orthovanadate, 20 
mMβ-glycerophosphate and protease inhibitors (Sigma-
Aldrich, Steinheim, Germany). Lysates were centrifuged 
at 10,000 g for 15 minutes at 4°C and supernatants were 
stored at −80 °C. Protein concentration was measured 
by the Bradford Assay (#500-0006; Bio-Rad, München, 
Germany). Thirty microgram aliquots of proteins were 
re-suspended in a reducing Laemmli Buffer (with 
β-mercaptoethanol), loaded onto a 10% polyacrylamide 
gel, and then transferred to nitrocellulose membranes. 
After blocking with 5% milk (Fluka, Sigma-Aldrich, 
Saint Louis, USA), the membranes were incubated with 
specific antibodies. Horseradish peroxidase-conjugated 
IgG preparations were used as secondary antibodies, 
and the immunoreactivity was determined by the 
enhanced chemiluminescence (ECL) method (Amersham, 
Buckinghamshire, UK). The autoradiograms were 
scanned and exported for densitometry analysis. Protein 
signal intensities were measured using the Quantity One 
Software (Bio-Rad Laboratories, Hercules, CA, USA). 
Signal quantity was normalized using the unrelated 
proteins β-actin (Cell Signaling Technology, Beverley, 
MA, USA), or GAPDH (Abcam plc, Cambridge, UK).
Quantitative real-time expression analysis
Leukemic blasts were obtained after Ficoll-Hypaque 
centrifugation of bone marrow mononuclear cells. Total 
RNA was extracted using Trizol (Life Technologies, 
Invitrogen, USA). For cell lines, 2 x 106 cells were 
collected as starting material for RNA extraction. Reverse 
transcription was performed on 1 μg total RNA using a 
standardized protocol (Applied Biosystems, Foster City, 
USA). The primers were obtained from IDT (San Jose, 
California, USA). Primer sequences were ABL-foward5’-
TGGAGATAACACTCTAAGCATAACTAAAGGT-3’, 
ABL-reverse: 5’-GATGTAGTTGCTTGGGACCCA-3’ 
and ABL-probe 5’-FAM-
CCATTTTTGGTTTGGGCTTCACACCATT-BHQ-3’; 
PTEN-foward5’-GCTCTATACTGCAAATGCTATCG-3’; 
PTEN-reverse5’-CCACAAACAGAACAAGATGCT-3’; 
PTEN-probe: 5’-FAM/TCTTCATAC/ZEN/
CAGGACCAGAGGAAACCT/3IABkFQ/-3’.
 Expression levels of the genes of interest and of the 
control were quantitated using TaqMan® Universal PCR 
Master Mix (Applied Biosystems, Warrington, UK).
Reporter plasmids and luciferase assay
The PTEN regulatory promoter region was 
subcloned in PGL4.1 FLuc reporter plasmid (Promega, 
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Madison, USA), using the following primers: forward: 
5’-CCCTCTTTAGACTTTGCTAGGC-3’ and reverse: 
5’-GGTAGGAGGGGGCAGAGC-3’. NB4 cells were 
electroporated using the Amaxa Nucleofector system 
according to the manufacturer’s protocol. Briefly, 2 x 
106 cells were co-transfected with 2 ug of PGL-4 PTEN 
promoter and 200 ng of pRLTK plasmid (Promega, 
Madison, USA) encoding for renilla luciferase gene as 
internal control. Electroporation was performed by re-
suspending the cells in 100 μl Cell Line Nucleofector® 
Solution V, Program X-001. Immediately after 
electroporation, cells were treated with 1uM ATRA 
for 48hrs. Luciferase was measured using the Dual-
Luciferase Reporter Assay System (Promega, Madison, 
USA), according to the manufacturer’s instructions. 
Luminescence was measured with the “Dual Glow” 
protocol of the Glowmax MULTI + Detection System 
(Promega, Madison, USA).
ChIP assay
ChIP assays were performed as previously described 
[37], with some modifications. Briefly, DNA was double-
crosslinked to proteins with 1% formaldehyde (Sigma, 
St Louis, USA). After incubation for 10 minutes at RT, 
glycine was added to a final concentration of 0.125 M, 
for 5 minutes. The cells were washed twice with PBS 1 
x, cell lysis buffer (10 mMTris pH 8.0, 100 mMNaCl and 
0.2 % NP40) was added to the samples and incubated on 
ice for 30 minutes. Nuclei were pelleted by microfuge 
at 1500 rpm at 4°C, and after addition of the nuclear 
lysis buffer (50 mMTris 8.1, 10 mM EDTA and 1 % 
SDS) were incubated on ice for 30 minutes. Chromatin 
fragments of around 200–300 bp were obtained by 
sonication, using a Branson Sonifier 450 Analog Cell 
Disruptor (30″ON, 45″ OFF, for a total time of 10 
minutes at output 2). For each immunoprecipitation, 3 
mg of antibodies were conjugated to magnetic beads 
(G-protein magnetic Beads, Invitrogen, Dynal, Oslo). 
The following antibodies were used in the ChIP assays: 
anti-PU.1 (T-21, sc-352, Santa Cruz Biotechnology, Inc. 
Dallas, USA), anti PML (H-238, sc5621, Santa Cruz 
Biotechnology, Inc.Dallas, USA), anti-Actil-Histone H3 
(Lys14), anti-trimethyl-Histone H3 (Lys27) (#06-599 and 
07-449, Millipore,Darmstadt, Germany), anti-Histone 
H3 (ab1791, Abcam,Cambridge, UK) and normal rabbit 
IgG (#2729, Cell Signaling Inc. Massachusetts, USA). 
After extensive washing, bound DNA fragments were 
eluted and analyzed by quantitative PCR using the SYBR 
Green Master Mix (Applied Biosystems,Warrington, 
UK). ChIP signals were normalized against the input 
and expressed as relative enrichment of the material, 
precipitated by the indicated antibody binding to the 
PTEN promoter [relative quantification using the 
comparative Ct method (2−(Ct sample−Ct input)]. 
Chip primers are: P1F-5’-gtgcgatccaactctcagca-3’ 
P1R-5’-GCAAGTCTGTTTACAGCCCCG-3’, 
P2D-5’-ggagctatcactggggagtg-3’ P2R-5’- 
GAGGAGACCTAGGAGGGTTC-3’; P3F-
5’-GCTAAGACTGACACCATGAGGAC-3’ 
P3R-5’-TCGGATCACAATCGTTCGCAG-3’ P4F-
5’-CAGGCTCCCAGACATGACAG-3’; P4R-
5’-CGAATCCATCCTCTTGATATCTC-3’. The 
GAPDH gene was used as a negative control; forward: 
5’-GTATTCCCCCAGGTTTACAT-3’ and reverse 
5’-TTCTGTCTTCCACTCACTC-3’.
Immunofluorescence assays
Cytospins from the NB4 cell line were 
prepared using a cytocentrifuge. Cells fixed with 4% 
paraformaldehyde (PFA) were permeabilized in PBS 
containing 0.2% Nonidet P-40 and blocked in 5% 
BSA. Slides were incubated overnight with the primary 
antibody (PTEN, clone 6H2.1, Cascade Bioscience 
Inc., Winchester, MA, USA), washed twice in PBS 
and incubated for 2 h with the secondary antibodies: 
Invitrogen Alexa Fluor 555-labeled goat anti-mouse 
(diluted 1:400 with PBS+BSA 2%). After nuclear 
counterstaining with 4′,6-diamidino-2-phenylindole 
(DAPI), slides were visualized using an Olympus BX61 
fluorescent microscope equipped with a CoolSNAP EZ 
camera (Photometrics, Tucson, AZ, USA). 
Transfection experiments
To evaluate the effect of PML/RARA on PTEN 
half life, Hek293T cells were transfected with pSG5-
PML/RARA or pSG5 constructs. Western blot assays 
were performed following treatment with the inhibitor of 
protein biosynthesis Cycloeximide (CHX) over 24 hours.
Statistical analysis and bioinformatics
All statistical analyses were conducted using the 
program GraphPad Prism5. Promoter sequences were 
retrieved from the National Center for Biotechnology 
Information online database (www.ncbi.nlm.nih.gov). 
Prediction of transcription factor binding sites was 
performed using the MatInspector (www.genomatix.de) 
and ALGGEN PROMO (http://alggen.lsi.upc.es) software. 
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